Definition, Diagnostic Criteria & Classification

Question	Answer
1. Define Chronic Kidney Disease (CKD) in children and detail the KDIGO Staging Criteria.	- Definition: Abnormalities of kidney structure or function persisting for $\ge 3$ months, characterized by either an eGFR $<60\text{ mL/min/1.73 m}^2$ OR evidence of structural/functional kidney damage (proteinuria, urinary sediment abnormalities, tubular disorders, or radiological renal dysplasia). - KDIGO GFR Staging ($\text{mL/min/1.73 m}^2$): - Stage 1: Kidney damage with Normal or high GFR ($\ge 90$). - Stage 2: Mild reduction in GFR ($60\text{ to } 89$). - Stage 3a: Mild-to-moderate reduction in GFR ($45\text{ to } 59$). - Stage 3b: Moderate-to-severe reduction in GFR ($30\text{ to } 44$). - Stage 4: Severe reduction in GFR ($15\text{ to } 29$). - Stage 5: Kidney Failure / End-Stage Kidney Disease ($<15$ or on chronic dialysis).
2. State the Updated Bedside Schwartz Equation (2009) and demonstrate its calculation.	$$
\text{eGFR } (\text{mL/min/1.73 m}^2) = \frac{0.413 \times \text{Height (in cm)}}{\text{Serum Creatinine (in mg/dL)}}
$$
- Example Calculation: For a 9-year-old boy, height $115.0\text{ cm}$, serum creatinine $2.1\text{ mg/dL}$:
$$
\text{eGFR} = \frac{0.413 \times 115.0}{2.1} = \frac{47.495}{2.1} = \mathbf{22.62\text{ mL/min/1.73 m}^2} \quad (\text{Stage 4 CKD})
$$
- Note: Uses a unified constant $k = 0.413$ across all pediatric ages ($1$ to $16$ years) calibrated to enzymatic, IDMS-traceable serum creatinine assays.
3. How does the etiological spectrum of pediatric CKD differ fundamentally from adult CKD?	In adults, Diabetic Nephropathy ($>40\%$) and Hypertensive Nephrosclerosis ($>25\%$) predominate. In children: 1) Congenital Anomalies of the Kidney and Urinary Tract (CAKUT, $>50\%$ of all cases): Renal hypoplasia/dysplasia, Posterior Urethral Valves (PUV), obstructive uropathy, and reflux nephropathy. 2) Glomerular Diseases ($15-20\%$): Steroid-Resistant Nephrotic Syndrome (FSGS), Lupus Nephritis, Atypical HUS. 3) Hereditary / Tubulointerstitial ($10-15\%$): Nephronophthisis, Cystinosis, Autosomal Recessive Polycystic Kidney Disease (ARPKD).
4. What are the clinical components of CKD-Mineral and Bone Disorder (CKD-MBD)?	A systemic disorder of mineral and bone metabolism manifested by any combination of: 1) Biochemical Abnormalities: Hyperphosphatemia, hypocalcemia, hyperparathyroidism (high iPTH), and low active vitamin D ($1,25[\text{OH}]_2\text{D}$). 2) Bone Disease (Renal Osteodystrophy): Abnormalities in bone turnover, mineralization, volume, linear growth, or bone strength (e.g., Osteitis Fibrosa Cystica, Adynamic Bone Disease, Genu Valgum). 3) Vascular & Soft Tissue Calcification: Metastatic arterial and cardiac valve calcification driven by an elevated Calcium-Phosphate Product ($\text{Ca} \times \text{P} > 55\text{ mg}^2/\text{dL}^2$).

Pathophysiology & Therapeutics

Question	Answer
5. Detail the multi-step biochemical pathophysiology of Secondary Hyperparathyroidism in CKD.	1) Phosphate Retention & FGF-23 Surge: Decreased nephron mass causes initial phosphate retention, triggering osteocytes to secrete massive Fibroblast Growth Factor 23 (FGF-23). 2) Suppression of 1-$\alpha$ Hydroxylase: High FGF-23 down-regulates renal CYP27B1 ($1\text{-}\alpha\text{ hydroxylase}$), dramatically halting conversion of $25(\text{OH})\text{D}$ to active $1,25(\text{OH})_2\text{D}$ (Calcitriol). 3) Hypocalcemia: Low calcitriol impairs intestinal calcium absorption, producing systemic hypocalcemia. 4) Loss of Parathyroid Feedback: Hypocalcemia and low calcitriol disinhibit Calcium-Sensing Receptors (CaSR) and Vitamin D Receptors (VDR) on parathyroid chief cells. 5) PTH Hypersecretion: Parathyroid hyperplasia causes massive secretion of Intact Parathyroid Hormone (iPTH), driving high-turnover bone resorption (Osteitis Fibrosa Cystica).
6. VIVA TRAP: What is the Calcium-Phosphate Product ($\text{Ca} \times \text{P}$), and why is it dangerous?	- Calculated by multiplying Serum Calcium ($\text{mg/dL}$) by Serum Phosphorus ($\text{mg/dL}$). - Critical Danger Threshold: $\text{Ca} \times \text{P} > 55\text{ mg}^2/\text{dL}^2$. - When this solubility threshold is exceeded, calcium phosphate precipitously crystallizes in vascular smooth muscle (coronary arteries, aorta), cardiac conduction tissue, and subcutaneous vessels (Calciphylaxis). Cardiovascular calcification is the leading cause of death in children and young adults with CKD!
7. Detail the management protocol for Anemia of CKD.	1) Target Hemoglobin: Maintain $10.5\text{ to } 11.5\text{ g/dL}$ (Do NOT normalize $>12.5-13\text{ g/dL}$ due to thrombosis and stroke risk). 2) Replenish Iron Stores FIRST (CRITICAL VIVA TRAP): Erythropoietin will fail without adequate iron availability! - Ensure Transferrin Saturation (TSAT) $>20\%$ AND Serum Ferritin $>100\text{ ng/mL}$. - Administer oral elemental iron ($2-3\text{ mg/kg/day}$) or IV iron sucrose if on hemodialysis. 3) Erythropoiesis-Stimulating Agent (ESA): - Recombinant Human Erythropoietin (rHuEPO): $50-100\text{ Units/kg/week}$ SC divided 1-2 times weekly, OR - Darbepoetin alfa: $0.45\text{ mcg/kg}$ SC every 1 to 2 weeks.

VIVA TRAPs & Counter-Questions

Question

Answer

8. VIVA TRAP: Why should severe dietary protein restriction NEVER be prescribed to a child with CKD?

While adult CKD guidelines historically advocated protein restriction to retard glomerulosclerosis, severe protein restriction in children is STRICTLY CONTRAINDICATED!
Growing children require substantial amino acids for somatic growth and cellular repair. Severe protein restriction precipitates Protein-Energy Wasting (PEW), worsens stunting, and significantly increases mortality.
Pediatric Target: Provide $100\%$ of Dietary Reference Intake (DRI) for protein based on chronological age, using high biological value sources (dairy, egg, poultry), with adequate non-protein calories!

9. Counter-Question Chain: "What is the preferred Renal Replacement Therapy (RRT) modality in young children with Stage 5 CKD, and why?"

- First-Line Modality: Automated Peritoneal Dialysis (APD) using a permanent cuffed Tenckhoff catheter.
- Advantages in Children:
1) Continuous, slow fluid and solute removal avoids the rapid hemodynamic shifts and 'dialysis disequilibrium' of hemodialysis.
2) Eliminates the need for difficult surgical arteriovenous fistulas in tiny blood vessels.
3) Performed at home during sleep, allowing uninterrupted school attendance and normal childhood social development.
4) Superior preservation of residual renal function.
- Ultimate Gold Standard: Pre-emptive Living Donor Renal Transplantation (ideally parental living donor before initiating chronic dialysis).